Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0025202 (melanoma)
 69,561 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-based colorimetric assay was developed and compared with 51Cr release from different adherent tumor cell targets (human squamous cell carcinoma lines of the head and neck established in our laboratory, melanoma, and colorectal carcinoma) using 5-7-day human lymphokine-activated killer cells and monocyte-depleted peripheral blood lymphocytes as effectors. With adherent tumor cell targets, MTT colorimetry was more sensitive than the 51Cr release assay in measuring the antitumor activity of effectors: median, 4385 (range, 988-8144) versus median, 1061 (range, 582-7294) lytic units (the number of effector cells required to lyse 20% of 5 x 10(3) targets)/10(7) effectors (P less than 0.01). Background effects (without effector cells) were comparable in 4-h assays (9% versus 10%) between MTT colorimetry and 51Cr release. In 24-h assays, MTT colorimetry showed higher antitumor activity (70-100% versus 40-60% lysis at 1:1 effector:target cell ratio) but lower background effects (6% versus 38%) than 51Cr release assay. Thus, MTT colorimetry was more sensitive, did not use radiolabeled targets, required fewer effector cells, and was easier, less expensive, and better adaptable to serial monitoring of effector cell function in cancer patients. This colorimetric assay is especially well suited to adherent tumor cell targets. The use of adherent tumor cell monolayers, as opposed to trypsinized single cell suspensions, provides an opportunity to measure interactions of effector cells with enzymatically unaltered solid tumor targets. Because of the greater sensitivity of the colorimetric assay, the transformation of MTT data into lytic units, as commonly used for 51Cr release assays, required an adjustment to avoid the extrapolation based on the exponential fit equation.
 ...
PMID:Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. 234 May 18

MPP+, an oxidative metabolite of a neurotoxin, MPTP, was found to be cytotoxic to human melanoma cell lines, HMV-II and SK-MEL-44. After 3 days of culture in the presence of MPP+, a larger amount of MPP+ was accumulated in HMV-II cells than in SK-MEL-44 cells, which correlated well with the melanin contents; HMV-II cells contain larger amounts of melanin than SK-MEL-44 cells. After 6 days of culture in the presence of MPP+, the cytotoxicity of MPP+ on these cell types was evaluated by counting cell numbers with the dye exclusion test and double-layer soft agar clonogenic assay. It was found that exposure to MPP+ reduced the survival of HMV-II cells more significantly than that of SK-MEL-44 cells. In HMV-II cells, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay was used to elucidate the mechanism of MPP+ lethality. The formazan formation was reduced markedly by the presence of MPP+ at concentrations much lower than those required for cell death. These results suggest that cytotoxicity of MPP+ may be ascribed to its accumulation due to high affinity for melanin, and to inhibition of the enzymes utilizing ubiquinone in the mitochondrial respiratory chain.
 ...
PMID:Cytotoxic effect of 1-methyl-4-phenylpyridinium ion on human melanoma cell lines, HMV-II and SK-MEL-44, is dependent on the melanin contents and caused by inhibition of mitochondrial electron transport. 239 Feb 89

Cyanation of quinocarcin readily opened the oxazolidine ring to provide DX-52-1 (2), which was a key compound in the synthesis of quinocarcin derivatives. Various electrophilic reactions toward aromatic ring of DX-52-1 were examined, and 10-substituted (e.g., halogen, nitro, formyl, cyano, hydroxy, etc.) analogs were prepared. Dehydrocyanation of the derivatives could be achieved to reproduce the oxazolidine ring upon treatment with HCl or AgNO3. 10-Chloride 10 and 10-bromide 11 were the most promising among the derivatives prepared. Antitumor activity of 10 was extended to B-16 melanoma.
 ...
PMID:Synthesis and biological evaluation of quinocarcin derivatives. 239 52

The combined application of DNA unwinding and strand-scission agents is a novel and potentially important approach to cancer therapy, based in part on mechanistic considerations of drug action. In order to evaluate this hypothesis a number of experiments were performed in which the cellular cytotoxicity of DNA reactive agents (ethidium bromide, adriamycin or cis-platinum) were evaluated alone and in combination with bleomycin, a strand-scission agent, using a number of different tumor cell systems in vitro. The results of these studies indicated that combinations of these agents were found to be much more effective than treatment with single drugs alone. This conclusion was warranted for the action of ethidium bromide followed by bleomycin with murine L1210 leukemia, melanoma B16-BL6 and human HeLa cells, and cis-platinum followed by bleomycin with L1210 and B16-BL6 cells. These data support previous findings in which synergistic growth inhibition of L1210 cells by ethidium bromide, followed by bleomycin was explained by a two-step mechanism; first, ethidium bromide introduces changes in DNA-conformation resulting in the facilitation of a second step in which bleomycin cleaves DNA more efficiently. Therefore, the rational use of combinations of DNA reactive agents based on mechanistic considerations should result with improved therapeutic regimens for the treatment of cancer.
 ...
PMID:An evaluation of the effects of combination chemotherapy in vitro using DNA-reactive agents. 241 31

The mechanism of human interleukin (IL)-1 beta-mediated cytolysis was studied in a human melanoma cell line, A375.6. Purified recombinant human IL-1 beta produced 50% cytocidal activity at 50 pg/ml. A variety of compounds were tested for their ability to interfere with A375.6 lysis. Compounds were added simultaneously with IL-1 beta (100 pg/ml), and tumor cytolysis was measured after 72 hr of culture by release of 125I from DNA of A375.6 cells labeled with [125I]-dUrd. A variety of anti-inflammatory/immunosuppressive agents (including auranofin, chloroquine, cyclosporin A, d-penicillamine) and several cyclooxygenase/lipoxygenase inhibitors (AA-861, BW755c, and indomethacin) lacked protective activity. Similarly, phospholipase inhibitors (mepacrine and 4-bromophenacyl bromide), putrescine, inhibitors of lysosomal activity (chloroquine and NH4Cl), calcium channel blockers (nifedipine and verapamil), calmodulin inhibitors (W-7 and calmidazolium), and inhibitors of ADP ribosylation (nicotinamide and 3-aminobenzamide) were inactive. In contrast, corticosteroids (dexamethasone, hydrocortisone, and paramethasone acetate), tilorone, and protein kinase C inhibitors (1-[5-isoquinolinyl-sulfonyl]-2-methylpiperazine and staurosporine) significantly inhibited IL-1 beta-mediated A375.6 cytolysis. These compounds also interfered with tumor necrosis factor-mediated lysis of A375.6, suggesting common mechanisms of tumor cytotoxicity by these monokines. This model may be useful for delineating intracellular biochemical events integral to IL-1 action.
 ...
PMID:Potent inhibition of interleukin 1 beta-mediated human melanoma (A375.6) lysis by corticosteroids, staurosporine, and tilorone. 262 25

Several potentially bis(alkylating) bis(quinones) (3-5) and 1,4- and 1,3-bis(alkylating) monoquinones (6-13) belonging to general structure 2,2'-ethylenebis[5-[(leaving group)methyl]-1,4-benzoquinone] (3-5) and 2,5- and 2,6-bis[(leaving group)methyl]-1,4-benzoquinone water-soluble and -insoluble classes were prepared by oxidative demethylation of the corresponding tetramethoxydiphenylethanes (17-19) and dimethoxybenzenes (24, 27, 36-39), respectively. Methods employed for the preparation of tetramethoxydiphenylethane intermediates involved (1) arylmethyl bromide coupling and (2) catalytic hydrogenation of stilbene intermediates derived via Wittig reaction of (arylmethyl)phosphonium salts with aryl aldehydes. However, in biological investigations using a subcutaneous B16 (hypoxic) melanoma tumor in BDF1 hybrid mice with cyclophosphamide as positive control the most interesting series of structurally related analogues were the potentially monoalkylating monoquinones of the 2-[(leaving group)methyl]-1,4-benzoquinone type (i.e., 14 and 15) having water-insoluble (acetoxy) and water-solubilizing (succinate) groups. Serial measurements of tumor size, and evaluation of increased life span, in response to drug treatment also revealed potentially 1,4-bis(alkylating) (bromomethyl)-1,4-quinone 7 and 1,3-bis(alkylating) (hydroxymethyl)-1,4-quinone 10 to have variable activity, but none of the potentially bis(alkylating) bis(quinones) showed antitumor properties in this model.
 ...
PMID:Mono and bis(bioreductive) alkylating agents: synthesis and antitumor activities in a B16 melanoma model. 273 96

The inhibition of tyrosinases from frog epidermis (Rana esculenta ridibunda), mushroom (Agaricus bisporus) and Harding-Passey mouse melanoma by halides is compared. In all cases, the inhibition is pH dependent, increasing when the pH decreases. The order of inhibition is I- greater than Br- greater than Cl- much greater than F- for frog epidermis tyrosinase, F- greater than I- greater than Cl- greater than Br- for mushroom tyrosinase and F- greater than Cl- much greater than Br- greater than I- for the mouse melanoma enzyme. These results are discussed in terms of the active site accessibility to exogenous ligands. The activation energies of the enzyme-catalysed L-dopa oxidation were also calculated, being the values 6.86, 17.01 and 20.25 kcal/mol for frog epidermis, mushroom and Harding-Passey mouse melanoma, respectively. A relationship between these values and the evolutionary adaptation of these enzymes is proposed.
 ...
PMID:Comparative study of tyrosinases from different sources: relationship between halide inhibition and the enzyme active site. 308 87

We have recently shown that glucocorticoids dramatically increase the number of interleukin 1 (IL 1) receptors on human peripheral blood mononuclear cells (PBMC) and that IL 1 selectively induces the phosphorylation of a cytosolic 65-kilodalton (kDa) protein (pp 65) in glucocorticoid-pretreated PBMC. We describe here the purification and biochemical characteristics of pp 65. 32P-Labeled pp 65 was purified to homogeneity from the cytosol fraction of IL 1 stimulated [32P]orthophosphate-labeled PBMC by sequential chromatography on Sephacryl S-200, high-performance liquid chromatography (HPLC) anion exchange, and hydroxyapatite HPLC. The purified pp 65 was homogeneous on sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis. The unphosphorylated 65-kDa protein (p 65) was also purified to homogeneity in a similar way. About 40 micrograms of purified 65-kDa protein was recovered from 5 x 10(8) PBMC. Analysis of the amino-terminal sequence of the purified pp 65 revealed the amino terminus of pp 65 to be blocked. Amino acid sequence analysis of a cyanogen bromide cleaved peptide showed pp 65 to be a unique protein whose protein sequence has not yet been reported. Studies of the distribution of p(p) 65 based on Western blotting using specific polyclonal rabbit antibody to p(p) 65 showed that p(p) 65 exists in a variety of cells such as neutrophils, monocytes, B lymphocytes, and myeloid cells. It could not be detected in the T cell leukemia cell line (MOLT), melanoma cells, and fibroblasts.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Purification and characterization of a cytosolic 65-kilodalton phosphoprotein in human leukocytes whose phosphorylation is augmented by stimulation with interleukin 1. 326 3

The relationship between DNA crosslinks and cell death as a result of exposure to melphalan (MLN) was studied in the F1 variant of B16 melanoma cells. The formation of DNA crosslinks is believed to represent the lethal lesion following exposure of cells to bifunctional alkylating agents. The production of DNA crosslinks by MLN was determined by the recently described ethidium bromide fluorescence assay [De Jong et al., Int. J. Cancer 37, 557 (1986)]. A direct correlation between the percentage of DNA crosslinks (Ct) and cytotoxicity of melphalan has not been previously reported utilizing the fluorescence assay. The cytotoxicity of MLN and the production of DNA crosslinks by this drug were determined following a 1-hr incubation at 37 degrees. The concentrations of MLN necessary to reduce colony growth to 37% of control and 10% of control were 6.7 microM (EC37) and 26 microM (EC10) respectively. Utilizing the ethidium bromide fluorescence assay (EFA), the relationship between MLN concentration (x axis) and DNA crosslinks expressed as Ct (y axis) was best described by a power curve (y = 0.28 x 0.81; r = 0.985). The respective Ct values at the EC37 and EC10 of MLN were 1.3 and 3.8%. It appears that the sensitivity of the EFA is similar to the alkaline elution assay and, in addition, that the EFA is less technically difficult to employ with tumor cells obtained from patients.
 ...
PMID:Correlation between the cytotoxicity of melphalan and DNA crosslinks as detected by the ethidium bromide fluorescence assay in the F1 variant of B16 melanoma cells. 340 Dec 50

The suitability of a colorimetric [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)] assay to the determination of cell viability following photoradiation therapy (PRT) of human breast and melanoma cell lines has been examined. Results have been shown to correlate with those obtained using a clonogenic assay system. Using the MTT assay system it was shown that differences occur in the susceptibility of both lines to PDT. In addition it has been demonstrated that both lines differ with respect to their ability to develop photosensitivity in the presence of hematoporphyrin derivative (HpD). In the absence of serum this difference is not as obvious. This MTT assay provides a valid, simple and semi-automatable system for assessment of PRT in vitro.
 ...
PMID:Use of a tetrazolium based colorimetric assay in assessing photoradiation therapy in vitro. 340 10


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>